Publications

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.

Goldswain H. et al, (2023), Genome Biol, 24

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Liew F. et al, (2023), eBioMedicine, 87, 104402 - 104402

Publisher Correction: A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.

Bahar MW. et al, (2022), Commun Biol, 5

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.

Huo J. et al, (2022), Cell reports

A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.

Bahar MW. et al, (2022), Commun Biol, 5

Switching of Receptor Binding Poses between Closely Related Enteroviruses

Zhou D. et al, (2022), Viruses, 14, 2625 - 2625

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.

Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.

Huo J. et al, (2022), Cell discovery, 8

Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study

Vink E. et al, (2022), Open Forum Infectious Diseases, 9

Production and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris.

Sherry L. et al, (2022), Viruses, 14

Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.

Siggins MK. et al, (2022), Immunology

Nonlytic cellular release of hepatitis A virus requires dual capsid recruitment of the ESCRT-associated Bro1 domain proteins HD-PTP and ALIX.

Shirasaki T. et al, (2022), PLoS pathogens, 18

Delineating organizational principles of the endogenous L-A virus by cryo-EM and computational analysis of native cell extracts

Schmidt L. et al, (2022)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.

Wei J. et al, (2022), Nat Commun, 13

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022)

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei J. et al, (2022), Nature Medicine, 28, 1072 - 1082

An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status

Lumley SF. et al, (2022), Clinical Infectious Diseases, 74, 1208 - 1219

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei J. et al, (2022), Nature Medicine

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Purification of African Swine Fever Virus.

Shimmon GL. et al, (2022), Methods in molecular biology (Clifton, N.J.), 2503, 179 - 186

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.

Huang K-YA. et al, (2022), Theranostics, 12, 1 - 17

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Dejnirattisai W. et al, (2021), Lancet (London, England)

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2021)

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective.

Halawa S. et al, (2021), Nature reviews. Cardiology

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Tan TK. et al, (2021), Nature Communications, 12

Bacteriophage PRD1 as a nanoscaffold for drug loading.

Duyvesteyn HME. et al, (2021), Nanoscale

Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines

Bahar MW. et al, (2021), npj Vaccines, 6

Sex in Chemsex: Sexual Response, Motivations, and Sober Sex in a Group of Italian Men Who Have Sex With Men With Sexualized Drug Use.

Nimbi FM. et al, (2021), The journal of sexual medicine, 18, 1955 - 1969

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.

Liu C. et al, (2021), Cell host & microbe

iNEXT-Discovery and Instruct-ERIC: Integrating High-End Services for Translational Research in Structural Biology.

Wienk H. et al, (2021), Journal of visualized experiments : JoVE

Chems4EU: chemsex use and its impacts across four European countries in HIV-positive men who have sex with men attending HIV services.

Whitlock GG. et al, (2021), HIV medicine, 22, 944 - 957

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status

Eyre DW. et al, (2021), Clinical Microbiology and Infection, 27, 1516.e7 - 1516.e14

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

Wei J. et al, (2021), Nature Microbiology, 6, 1140 - 1149

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers

Lumley SF. et al, (2021), Clinical Infectious Diseases, 73, e699 - e709

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu C. et al, (2021), Cell, 184, 4220 - 4236.e13

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021)

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021)

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021)

Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation.

Allen JD. et al, (2021), Biochemistry, 60, 2153 - 2169

Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.

Redhead MA. et al, (2021), Scientific reports, 11

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Dejnirattisai W. et al, (2021), Cell, 184, 2183 - 2200.e22

Site-specific steric control of SARS-CoV-2 spike glycosylation.

Allen JD. et al, (2021), bioRxiv

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Huo J. et al, (2021), Nature Structural & Molecular Biology, 28, 326 - 326

Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey

Pouwels KB. et al, (2021), The Lancet Public Health, 6, e30 - e38

Cookies on this website

Publications